Detection of CSF Next Generation Sequencing in the Application of Brain Metastases From Lung Adenocarcinoma or Meningeal Metastasis
CSF
1 other identifier
observational
50
0 countries
N/A
Brief Summary
This study aimed to detect cell free DNA (cfDNA) in the cerebrospinal fluid and plasma, and to determine whether cfDNA can be used for concomitant diagnosis to improve the treatment efficacy and prognosis of patients with brain (meningeal) metastasis by monitoring tumor-related genetic mutations in cfDNA in the plasma and cerebrospinal fluid.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2017
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedFirst Submitted
Initial submission to the registry
January 20, 2017
CompletedFirst Posted
Study publicly available on registry
January 24, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2018
CompletedJanuary 24, 2017
January 1, 2017
1 year
January 20, 2017
January 23, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
investigate new diagnosis method for lung adenocarcinoma with brain (meningeal) metastasis
Investigate whether the cfDNA can be used for concomitant diagnosis to improve the treatment efficacy and prognosis of patients with brain (meningeal) metastasis by monitoring tumor-related genetic mutations in cfDNA in the plasma and cerebrospinal fluid.
Participants are followed in 6 months after treatment
Study Arms (1)
lung adenocarcinoma with brain (meningeal) metastasis
Eligibility Criteria
Ages Eligible for Study: 18 Years and older (Adult, Senior) Sexes Eligible for Study: All Accepts Healthy Volunteers: No
You may qualify if:
- Patients with confirmed diagnosis of lung adenocarcinoma with brain (meningeal) metastasis.
- Samples collection should be allowed.
You may not qualify if:
- Pregnant women
- Minors (subjects less than 18 years of age)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Wang Y, Luo N, Gao Y, Wu Y, Qin X, Qi Y, Sun T, Tao R, Qi C, Liu B, Yuan S. The joint detection of CEA and ctDNA in cerebrospinal fluid: an auxiliary tool for the diagnosis of leptomeningeal metastases in cancer. J Cancer Res Clin Oncol. 2023 May;149(5):1679-1690. doi: 10.1007/s00432-022-04053-7. Epub 2022 May 18.
PMID: 35583828DERIVED
Biospecimen
Anticoagulated whole blood, anticoagulated cerebrospinal fluid and tumor tissue were collected. DNA was extracted from tumor tissues, genomic DNA was extracted from leukocytes, and cfDNA was extracted from plasma and cerebrospinal fluid.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 6 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Shandong Cancer Hospital and Institute
Study Record Dates
First Submitted
January 20, 2017
First Posted
January 24, 2017
Study Start
January 1, 2017
Primary Completion
January 1, 2018
Study Completion
December 1, 2018
Last Updated
January 24, 2017
Record last verified: 2017-01
Data Sharing
- IPD Sharing
- Will not share